Celcuity ^{Priced, Nasdaq: CELC}

We are a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. Our proprietary CELx diagnostic platform is the only commercially ready technology we are aware of that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that best treats it. This enables us to diagnose new cancer sub-types molecular diagnostics cannot detect and to measure directly the effectiveness of the matching targeted therapy in a patient's living tumor cells. Our first commercially ready test is our CELx HER2 Signaling Function Test (CELx HSF Test), which diagnoses two new breast cancer sub-types that traditional molecular diagnostics cannot detect.